Tuesday, March 28, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Industry News

Roche Continues Hostile Takeover Efforts at Illumina

by Global Biodefense Staff
April 5, 2012

An eagerly anticipated vote at the Annual General Meeting of Illumina shareholders on April 18, 2012 will bring to a head the hostile takeover campaign underway by Roche Holding AG.  After Illumina rejected initial offers, Roche raised the stakes last week by increasing the price offered per share by 15 percent to a total of about $6.7 billion. Illumina, a California based maker of gene-mapping tools and diagnostics, has until 6 p.m. on April 20 to tender their stock at $51 a share.

The Basel-headquartered Roche group issued a second letter to shareholders urging them to accept its bid and vote for its nominees at the meeting. The Illumina board countered with its own (and third) appeal to shareholders urging stockholders to reject Roche’s efforts to acquire the firm, noting that that Illumina’s next-generation sequencing technology was poised as a leading player in research and clinical settings.

In the letter, Illumina says that “the molecular diagnostics space alone represents a $3 billion long-term growth opportunity” and its platforms “are already being adopted by leading diagnostic reference labs such as Sequenom, Genomic Health, Partners Healthcare and many others”.  Illumina is partnering with firms such as Siemens Healthcare, deCode Genetics and the Fred Hutchinson Cancer Center to develop diagnostic kits that they believe will eventually be used in thousands of hospital labs worldwide.

The board concluded that that future market opportunties were very positive. “Assuming a $1,000 cost per genome and only 1% penetration, (opportunties) could easily result in more than $600 million of new revenue for Illumina”.

In addition to commercial markets, Illumina has a widespread presence across federal research laboratories including the USDA Agriculture Research Service, the National Institutes of Allergy and Infectious Diseases, Environmental Protection Agency, Animal and Plant Health Inspection Service, U.S. Army Medical Reasearch Institute of Infectious Diseases and the Centers for Disease Control.

Related Posts

small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
DoD Awards ENA Respiratory $4.38M for Broad-Spectrum Antiviral Development
Industry News

DoD Awards ENA Respiratory $4.38M for Broad-Spectrum Antiviral Development

January 10, 2023
Bavarian Nordic to Supply Additional Monkeypox Vaccine to EU Member States
Industry News

Bavarian Nordic to Supply Additional Monkeypox Vaccine to EU Member States

September 7, 2022
Arcturus Awarded $63.2M to Advance Self-amplifying mRNA Vaccine for Pandemic Influenza Response
Industry News

Arcturus Awarded $63.2M to Advance Self-amplifying mRNA Vaccine for Pandemic Influenza Response

August 31, 2022
Load More

Latest News

Biodefense Headlines – 26 March 2023

March 26, 2023
Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC